If you plan to start retatrutide treatment for weight loss, consult your healthcare provider who will review your medical history, health goals, and decide if the medication is right for you.
is supported by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, UM1AI109568, OT2OD032581 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264
Similarly, an analysis utilizing the UK Clinical Practice Research Datalink (CPRD) revealed that GLP-1 RAs were linked to an increased incidence of intestinal obstruction requiring hospitalization, compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors (1.9 vs
Back Holst, JJ (2024) The Story of GLP-1: A historical journey in the treatment of diabetes and obesity